India's regulatory reforms since 2013 and the New Drugs and Clinical Trial Rules of 2019 have made it an attractive destination for clinical trials and shortened the approval process, according to a report by PwC India and US-India Chamber of Commerce. Contributing only about 4% annually to global clinical trials since 2010, India's clinical trial activity has been increasing steadily since 2014 due to the regulatory harmonisation, allowing open access to clinical trials in the country. India's diverse population and developing healthcare infrastructure create a conducive environment for clinical trials to succeed, the report noted.